title: Stimulation of central D1 dopamine receptors reverses reserpine-induced hypothermia in mice.
abstract: In mice rendered poikilothermic by a prior (18 h) subcutaneous administration of reserpine (3 mg/kg) the injection of the D1 dopamine agonist SKF 38393 in doses of 1 mg/kg or more increased dose-dependently, the body temperature. The D1 dopamine antagonist SCH 23390, administered subcutaneously, antagonized, with an ID50 of 16 micrograms/kg, the reversal by SKF 38393 of reserpine-induced hypothermia. The intracerebroventricular administration of 1 microgram per mouse of SKF 38393 was sufficient to elevate by about 7 degrees C the temperature of reserpinized mice. It is concluded that stimulation of central D1 dopamine receptors leads to a marked reversal of reserpine-induced hypothermia; this may constitute a new test to investigate interaction of drugs with these receptors. In reserpine-pretreated mice, the dopamine (DA) agonist apomorphine, which stimulates both the D1 and D2 subtypes of DA receptors, increases body temperature according to a mechanism insensitive to the specific D2 DA antagonist sulpiride (Horowski 1978) or the preferential D2 DA antagonist haloperidol (Danielson, Coutts, Keashly and Tang 1985). This observation led us to believe that D1 DA receptors could be involved in the reversal of the hypothermia induced by reserpine. To check more directly the involvement of D1 DA receptors in the reversal of the reserpine-induced hypothermia we have tested the specific D1 agonist SKF 38393 (Setler, Sarau, Zirckle and Saunders, 1978), administered peripherally or intracerebroventricularly and we have studied its interaction with the specific D1 antagonist SCH 23390 (Iorio, Barnett, Leitz, Houser and Korduba, 1983).
authors.affiliation: Unité de Neuropsychopharmacologie expérimentale, UA 1170 du CNRS, U.F.R. de Médecine et Pharmacie de Rouen, France.
authors.forename: D
authors.initials: D
authors.lastname: Duterte-Boucher
authors.forename: C
authors.initials: C
authors.lastname: Panissaud
authors.forename: A
authors.initials: A
authors.lastname: Michael-Titus
authors.forename: J
authors.initials: J
authors.lastname: Costentin
mesh_terms: D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D000284:Administration, Oral; D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D001831:Body Temperature / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects; D015259:Dopamine Agents / Q000494:pharmacology; D007279:Injections, Subcutaneous; D008297:Male; D051379:Mice; D011954:Receptors, Dopamine / Q000187:drug effects*; D012110:Reserpine / Q000037:antagonists & inhibitors* / Q000494:pharmacology
chemical_list: D001552:Benzazepines; D015259:Dopamine Agents; D011954:Receptors, Dopamine; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D012110:Reserpine